Tech Company M&A Transactions
Ceregene Acquisition
Ceregene was bought by Sangamo BioSciences. The transaction occurred on 8/27/2013. The transaction price was $1 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/27/2013
Transaction Type
M&A
Amount
$1,000,000
M&A Terms
Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, which represents less than 0.2 percent of Sangamo's total shares outstanding. In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9381 Judicial Dr. 130
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Using gene therapy delivery systems, Ceregene's primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Ostrove
Chief Scientific Officer
Raymond Bartus
Controller
Carolyn Bonebright
Browse more venture capital transactions:
Prev: 8/27/2013: Blue Cod Technologies venture capital transaction
Next: 8/27/2013: Credorax venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs